FIELD: medicine, endocrinology. SUBSTANCE: invention relates to agents used for prophylaxis and treatment of patients with diabetic complications including 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)-benzyl]-3,5-dimethylbenzoic acid, its optically active compound or its pharmaceutically acceptable salt as an active component. Invention relates to also a pharmaceutical composition and method of prophylaxis and treatment of patients with diabetic complications, in part, to diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis. Proposed drug shows the prolonged effect in very low doses being in a single every day administration. EFFECT: enhanced effectiveness of agent. 27 cl, 7 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STIMULATOR AGENTS FOR MAG EXPRESSION | 2000 |
|
RU2241454C2 |
| USE OF RKS INHIBITORS IN DIABETES RELATED COMPLICATIONS | 2007 |
|
RU2447892C2 |
| MEDICINAL AGENTS FOR TREATMENT OF COMPLICATIONS ASSOCIATED WITH DIABETES MELLITUS AND NEUROPATHY AND THEIR USING | 2001 |
|
RU2281764C2 |
| USE OF SIGMA LIGANDS IN DIABETES TYPE-2 ASSOCIATED PAIN | 2012 |
|
RU2608943C2 |
| APPLICATION OF 3-HYDROXY-3-METHTYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS IN PRODUCING MEDICINAL AGENT FOR TREATMENT OF DIABETIC NEUROPATHY | 2000 |
|
RU2239456C2 |
| PYRAZOLE-AMIDE COMPOUND AND MEDICINAL USES THEREFOR | 2014 |
|
RU2664532C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING CARBAMOYLOXYARYLALCANOYLARYLPIPERAZINE COMPOUND | 2011 |
|
RU2630619C2 |
| THIAZOL DERIVATIVE AND USING IT AS VAP-1 INHIBITOR | 2009 |
|
RU2496776C9 |
| COMPOUNDS FOR METABOLIC DISORDER TREATMENT | 2004 |
|
RU2349584C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING ALDEHYDE REDUCTASE INHIBITOR AND ACE INHIBITOR | 1998 |
|
RU2216354C2 |
